Delayed Sensitivity and Homograft Sensitivity

Publisher Website
Google Scholar
Abstract
Humoral antibody, as an effector of homograft rejection, is most potent against dissociated tumor cell homografts. It is suggested that this unique vulnerability is a function of the dissociated state and rapid growth rate inherent in that type of homograft. On the other hand, delayed sensitivity and cell-bound immune factors appear to play a predominant role in the rejection of solid homografts. A mutually exclusive selection of delayed sensitivity over humoral antibody, or vice versa, is not warranted by the facts currently available, nor would such a selection serve any useful purpose. Humoral antibody may play a role in the rejection of orthotopic skin grafts, despite the difficulties encountered to date in its detection. From the evidence reviewed, however, it would appear that the role would be a subsidiary one.